Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis

Atopic dermatitis (AD) affects 3% to 10% of adults.1Sacotte R. Silverberg J.I. Epidemiology of adult atopic dermatitis.Clin Dermatol. 2018; 36: 595-605Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar Recently, the increased understanding of AD pathogenesis has led to development of new treatments, including dupilumab, the first US Food and Drug Administration–approved biologic for moderate-to-severe AD. Although TH2 skewing is...